Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity.

MAbs · 2023 · PMC10072072 · PMID 36991534

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Interestingly, for the strongest CD3 affinity bispecifics (whose CD3 Fvs were optimized to reduce polyreactivity), there appears to be a positive trend between affinity and AC-SINS.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.